

ForPatients

by Roche

Non-Small Cell Lung Cancer (NSCLC) Triple Negative Breast Cancer Bladder Cancer
Colorectal Cancer (CRC) Malignant Melanoma Renal Cell Cancer (RCC) Non Small Cell
Lung Carcinoma Melanoma Head and Neck Cancer

A Study of RO7198457 (Personalized Cancer Vaccine [PCV]) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors

Trial Status
Active, not recruiting

Trial Runs In
8 Countries

Trial Identifier
NCT03289962 2017-001475-23
GO39733

The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.

Trial Summary:

This is a Phase 1a/1b, open-label, multicenter, global, dose-escalation study designed to evaluate the safety, tolerability, immune response, and pharmacokinetics of autogene cevumeran (RO7198457) as a single agent and in combination with atezolizumab (MPDL3280A, an engineered anti-programmed death-ligand 1 [anti-PD-L1] antibody).

Genentech, Inc.
Sponsor

Phase 1
Phase

NCT03289962 2017-001475-23 GO39733
Trial Identifiers

Eligibility Criteria:

Gender
All

Age
≥ 18 Years

Healthy Volunteers
No
